Abstract
Objective Current methods for early detection of hypoxic–ischemic encephalopathy (HIE) are limited by lack of specificity, cost, and time constraints. Blood tau protein concentrations reflect neuropathology in adults. This study examines tau as a potential HIE biomarker in neonates by relating cord blood levels to short-term fetomaternal outcomes.
Design Prospective cohort study.
Setting Royal Prince Alfred Hospital—a large Australian tertiary referral centre. Population: 107 maternal participants.
Methods Simoa analysis of umbilical cord blood pTau217 and brain-derived (BD)-tau.
Main Outcome Measures Primary: association of BD-tau with non-reassuring fetal status. Secondary: 1) correlations between cord blood tau and other biomarkers; 2) associations between tau levels and risk factors for fetomaternal morbidity; 3) associations between tau levels and short-term fetomaternal outcome.
Results Of 509 deliveries, cord blood was analysed in 107/110 recruited maternal participants. BD-tau correlated with non-reassuring fetal status (OR=3.0;95%CI=1.6– 5.7;p=0.001), though not when adjusting for mode of delivery and gestational age. BD-tau was higher in vaginal deliveries, and positively associated with pTau217, NfL, and lactate (p<0.001), and negatively associated with pH and base excess. pTau217 was higher in preterm neonates and was associated with neurofilament light chain (Spearman’s rho=0.44,p<0.001). BD-tau and pTau217 were associated with maternal hypertension and placental abnormalities.
Conclusions Cord blood BD-tau correlates with markers of fetal hypoxia, whilst pTau217 levels may indicate broader neurodevelopmental vulnerability. Further studies could explore whether these findings translate to clinical use of tau as an HIE biomarker.
Funding US National Institutes of Health (grant:R01AG063849-01).
Competing Interest Statement
HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).
Funding Statement
The work is supported by US National Institutes of Health (NIH) grant R01 AG063849–01 (RDS). NIH R01 grants are subject to external peer review for scientific quality, and priority score is based advisory council assessment. KB is supported by the Swedish Research Council (#2017–00915 and #2022–00732), the Swedish Alzheimer Foundation (#AF–930351, #AF–939721, #AF–968270, and #AF–994551), Hjärnfonden, Sweden (#FO2017–0243 and #ALZ2022–0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG–715986 and #ALFGBG–965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer舗s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer舗s Association 2022–2025 Grant (SG–23–1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, and the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark. HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023– 00356; #2022–01018 and #2019–02397), the European Union舗s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG–71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809–2016862), the AD Strategic Fund and the Alzheimer舗s Association (#ADSF–21–831376–C, #ADSF–21–831381–C, #ADSF–21–831377–C, and #ADSF–24–1284328–C), the Bluefield Project, Cure Alzheimer舗s Fund, the Olav Thon Foundation, the Erling–Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022–0270), the European Union舗s Horizon 2020 research and innovation programme under the Marie Skłodowska–Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021–00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI–1003).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was granted by the Sydney Local Health District Human Research and Ethics Committee (approval reference: 2022/ETH01100). Data were reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors subject to ethics approval constraints.
